Introduction
SLE is a chronic, multisystem autoimmune disease with a highly variable clinical course. Pediatric-onset SLE (pSLE) is associated with higher disease severity than adult onset SLE. AIHA may be the initial manifestation of SLE or may develop throughout the disease course. One potential strategy for the treatment of SLE in addition to corticosteroids is targeting B cells. [1, 2] Belimumab is a human monoclonal antibody that specifically binds to the soluble B-lymfocyte stimulator (BLyS), thereby preventing it from binding to receptors on the surface of B cells. The US Food and Drug Administration (FDA) approved the use of Belimumab for auto-antibody-positive adult SLE patients in March 2011. So far, no studies were reported on the use of Belimumab under the age of 18 years. We present a 14 year old girl with a relapse AIHA in the context of a SLE, who was treated with belimumab.
Case report A 4 year old girl was diagnosed with a refractory autoimmune hemolytic anemia characterized by a positive direct antiglobulin test (IgG) and the presence of both warm and cold auto antibodies in variable titers. Complement was detectable on the erythrocytes. She did not achieve stable remission in 9 years despite almost continuously corticosteroids combined with 2 times 3 courses of rituximab, ciclosporine, azathioprine and a splenectomy.
At the age of almost 13 she developed a full-blown SLE with a malar rash, cutaneous vasculitis, WHO-class 4 nephritis, interstitial lung disease (based on a HRCT and mild impairment of the diffusion capacity), positive anti nuclear antibody and positive anti-double stranded DNA antibody (ds-DNA) (226 IU/ml, normal 0-15IU/ml), photosensivity, low complement levels of C3-C4 and positive phospholipid antibodies. SLEDAI score at that moment was 44. She was treated with 6 pulses of cyclofosfamide (2 times 750mg/m² and 4 times 550 mg/m²), high doses of prednison (50mg/day = 1mg/kg/day) and hydroxychloroquine. The treatment was complicated by a Morganella Morganii sepsis meningitis after the first cyclofosfamide infusion. At that time MRI showed a sinus thrombosis and old lesions most likely caused by a cerebral vasculitis or previous thrombus. Anti-coagulation therapy was started.
Four months after the induction with cyclofosfamide was started, she was in clinical remission without any signs of hemolysis. ds DNA levels returned to normal, ESR remained elevated (52 mm/h, normal 0-20 mm/h) and complement levels remained low. (See figure 1) MMF was started as a maintenance therapy (2000 mg/day) six month after the start of the induction. At that moment, all laboratory parameters were normalized, except for the hematuria which resolved 5 months later.
Fourteen months after starting maintenance therapy a relapse of the hemolysis occurred based on elevated LDH levels, low haptoglobin levels and elevated reticulocytes count, without systemic involvement. (See figure 1) The SLEDAI score at that moment was 4 based on low complement levels and increased dsDNA. No remission was accomplished by increasing the MMF from 2000 to 3000mg and the prednisone from 5 mg every other day to 10 mg/day. Her therapeutic options were limited given her previous exposure to cyclofosfamide and the inefficacy of rituximab, ciclosprin and azathioprin. Treatment with steroids was complicated by a vertebral fracture and growth retardation. For that reason we considered Belimumab as the next treatment option. Patient and both parents were consented for this off-label use of Belimumab.
A month prior to belimumab treatment, the prednisone was elevated to 40 mg/day to achieve stable disease. Resulting in normalization of hemoglobin (Hb) levels but there were still signs of hemolysis (elevated reticulocyte count, elevated LDH levels and lowered haptoglobin levels). (See figure 1) Belimumab 10mg/kg intravenously was administered at day 1-14-28, followed by a four weeks treatment. Hemolysis resolved and dsDNA levels normalized within 2 months after starting Belimumab. LDH levels remained slightly elevated interpreted as due to blood collection procedure. Complement levels improved but remained just above the lower limit of normal. (See figure 1) The number of CD19 positive B cell count deceased from 0.54 to 0.04 x10E9/l after 10 months of treatment. IgG levels were already low at start (5,1g/l) and deceased further to 4,1g/l after 11 months of belimumab treatment. The prednisone dose could be tapered from 40 to 12.5 mg a day. The patient was feeling well during the period of treatment and experienced no side effects like allergic reactions or infections.
Unfortunately, she had a relapse hemolysis after 11 months of therapy with a fall of Hb levels, increased reticulocyte count and elevated LDH. For this relapse she was recently treated with a course of Rituximab.
Discussion AIHA is an autoantibody-mediated immune disorder that affects both children and adults. In children the peak incidence is in the first 4 years of live especially in transient cases. The diagnosis of AIHA relies on the direct antiglobulin test (Coombs), which is a highly sensitive and relatively specific test and of course on the presence of hemolyse. In adults the classification of AIHA is based on the characteristic temperature reactivity of the red blood cell autoantibody (warm, cold and mixed type) and the etiology. AIHA may be primary (usually after an infection) or secondary to an underlying disease (for example autoimmune diseases and malignancies). [3] In children transient cases might be distinguished from prolonged cases not only on basis of the duration of the disease but also from the clinical and immunological standpoints (age at onset of the disease, the effectiveness of steroid therapy, type of Coombs test (complement-type versus IgG or mixedtype), the presence of an underlying disease and prodromic infections). [4] In adult patients the presence of warm autoantibodies is associated with a secondary disease like SLE; in children this is less clear. Our patient had both cold and warm autoantibodies and presence of complement on the surface of the erythrocytes. This mixed type of auto antibodies, her age of onset, duration of the disease and her poor response to steroids is more common in the chronic cases of AIHA which are associated with a higher incidence of SLE. [4] SLE is a chronic, multisystem autoimmune disease with a highly variable clinical course. Pediatric-onset SLE (pSLE) represents 10-20% of all SLE cases. It is associated with higher disease severity than adult onset SLE and the majority of pSLE patients develop damage within 5-10 years of disease onset, most frequently involving the musculoskeletal, ocular, renal and neuropsychiatric systems. [5] Hematological involvement has been reported to occur in 86% of the pSLE patients. Anemia, especially Coombs positive hemolytic anemia is the most common hematological finding. AIHA may be the initial manifestation of SLE, occurring in 21% (9/43) of the pSLE patients or may develop throughout the disease course, up to 50% (23/43) of the pSLE patients. [6] The presence of hemolytic anemia in adult SLE patients is associated with a subset of lupus characterized by a younger age of disease onset and a more severe disease. [7] The treatment of SLE mainly depends on the organ systems that are involved (especially nephritis). The cornerstone of treatment is still corticosteroids and although the use of other immunosuppressive drugs therapy like cyclofosfamide, cyclosporine, methotrexate and azathioprin has improved the treatment of SLE, a substantial proportion of patients do not achieve full remission and relapses are common. [8, 9] One potential strategy for the treatment of SLE in addition to corticosteroids is targeting B cells. [1, 2] Rituximab a monoclonal chimeric anti CD20 antibody is being used in a variety of autoimmune diseases and excellent response rates (75-87%) are seen in small series of children with AIHA. [10] Belimumab is a human monoclonal antibody that specifically binds to the soluble B-lymfocyte stimulator (BLyS), thereby preventing it from binding to receptors on the surface of B cells.
We present a pediatric patient with a relapse autoimmune hemolytic anemia (AIHA) as an isolated symptom of her SLE. The SLE was diagnosed according to the ACR criteria at the age of 13 years, after she suffered from AIHA from the age of 4 years. She was already treated with several immunosuppressive drugs, including rituximab, and increasing prednisone up to 40mg/day did not lead to remission of the AIHA so Belimumab was added. The efficacy and safety of Belimumab in patient' s ≥ 18years, with active autoantibody positive SLE was demonstrated in two large phase III clinical trials. [11, 12] So far, no studies have been done concerning safety and efficacy of Belimumab in patients of 18 years and younger. In our patient Belimumab was well tolerated and there were no side effects in the period of treatment. Since the follow up of this patient has been only one year, we can not comment on the long-term complications.
After a positive reaction in the first 11 months, unfortunately a relapse of hemolytic anemia occurred at a prednisone dose of 12, 5 mg/day.
The refractory nature of AIHA in SLE patients to Belimumab was already seen in other studies. Data on Belimumab trials regarding hematological symptoms are ambiguous. Combined results of two large phase III clinical trials on belimumab showed improvement of the overall disease activity in the most common musculoskeletal and mucocutaneous organ domains and less worsening in the hematological and immunological domains. [13] When comparing the overall activity in adult patients with our patient one might conclude that AIHA in SLE patients is less sensitive to belimumab treatment.
In addition, we know that the presence of AIHA in adult SLE patients is associated with a more severe disease course and that pSLE is a more severe disease than adult onset SLE that might require different treatment strategies. One could also imagine that the AIHA that eventually progresses to SLE is a more severe and chronic type of AIHA also requiring a different approach from the start. The ongoing autoimmune activity for so many years might influence the effectiveness of the belimumab.
The initial favorable response could also be explained by the increased dose of corticosteroids prior to the belimumab treatment. Another explanation could be the occurrence of anti-Belimumab antibodies. The fact that she had a good response eventually supports this theory. Furie at al showed that 2 out of 70 patients developed anti-belimumab antibody responses and a 2 to 3.5 fold decrease of serum belimumab concentrations than the predicted values. Only one had neutralizing antibodies [14] Unfortunately, the essays to measure anti-bodies or Belimumab concentrations are not generally available yet and clinical relevance is not exactly known. Another reason for the relapse could be that pharmacokinetics in children differ from that of adults so dose or dosing intervals should be adjusted. For we know, all research on the pharmacokinetics of Belimumab is done on adult patients. [14] Conclusion After an initial favorable response, our pediatric SLE patient had a flare of her AIHA while treated with Belimumab. There are multiple causes that could explain this. One might conclude that AIHA in SLE patients is less sensitive to Belimumab treatment or that pSLE is different from adult onset SLE requiring different treatment strategies. A significant proportion of children with SLE develop an AIHA somewhere in the course of their disease and AIHA seems to be associated with a more severe disease. This and the fact that long-term prednisone treatment is accompanied with serious side effects in children, stresses the need of future trials to show the efficacy of steroid sparing drugs like belimumab on AIHA in SLE patients, especially in children.
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